ESMO26: Iza-bren leads post-TKI ADCs on efficacy, but toxicity could decide
On 26 October 2026, Li Zhang presented the Phase III PANKU-Lung01 trial at the European Society for Medical Oncology (ESMO) …
Post
-
-
Sobi’s gout drug shows durability in Phase III study
Sobi’s investigational gout therapy, pozdeutinurad, has been shown to meaningfully reduce levels of a key chemical that drives the disease …
-
Podcast: ESMO26: Major readouts from the 2026 congress
This year's European Society of Medical Oncology (ESMO) Congress has come to a close, with hundreds of studies having been …
-
Navigating the complexities of running clinical trials amid disruption
As the pharma and biotech sectors evolve at a rapid pace, one truth remains constant: disruptions, if not sufficiently accounted …
-
United Therapeutics secures FDA clearance for PAH Phase I trial
United Therapeutics has received clearance from the US Food and Drug Administration (FDA) under an investigational new drug application (IND) …
-
First patient dosed in Nacuity’s Phase III Usher syndrome RP trial
Nacuity Pharmaceuticals has dosed the first patient in its global confirmatory Phase III SLO-RP Preserve study, evaluating NPI-001 for retinitis …
-
Lilly’s retatrutide beats Ozempic in head-to-head trial
Eli Lilly, a dominant force in the obesity and type 2 diabetes market, has just beaten its biggest rival, with …
-
IDWeek 2026: BNT163 poised to fulfil a substantial unmet need for genital herpes
At the 15th annual IDWeek conference in Washington DC, Federico Mensa of BioNTech presented data on BNT163, a trivalent mRNA …
-
ESMO26: US and FDA movements to improve oncology trials a positive signal
Since the Trump Administration took office in the White House, there has been an uptick in the number of guidance …
-
Walmart and Care Access to open three clinical trial centres in US
The Walmart Healthcare Research Institute (WHRI) and Care Access are set to launch three further clinical trial centres in the …
-
Vanda reports Phase III tradipitant trial data in GLP-1-associated vomiting
Vanda Pharmaceuticals has reported positive results from the Phase III clinical trial, Study 3601 (VP-VLY-686-3601), assessing its oral therapy Nereus …
-
ESMO26: Other skin cancer advances beyond groundbreaking cancer vaccine
Arguably the most impactful readout in skin cancer in recent months was MSD and Moderna’s melanoma cancer vaccine data. At the …
-
ESMO26: Intismeran sets new benchmark in adjuvant melanoma
At the 2026 European Society for Medical Oncology (ESMO) Congress, full results from Merck and Moderna’s Phase III INTerpath-001 trial …
-
Retatrutide cost in 2026: What a research vial really costs and why the cheapest listing is a red flag
Search for retatrutide online and you’ll find prices that vary wildly. One listing asks a fair amount, the next asks …
-
IDWeek 2026: meropenem-pilabactam successfully targets critical priority pathogens
At the 15th annual IDWeek conference in Washington DC, Rienk Pypstra, MD, chief medical officer of Antabio, presented data on …
